Photo by markusspiske from unsplash
Foscarnet is an important drug for the treatment of cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation (HSCT). Foscarnet is often discontinued because of the development of acute kidney… Click to show full abstract
Foscarnet is an important drug for the treatment of cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation (HSCT). Foscarnet is often discontinued because of the development of acute kidney injury (AKI). Thus, the identification of factors leading to the development of AKI is beneficial. This study aimed to investigate the incidence of AKI and the factors influencing AKI development in HSCT patients treated with foscarnet.
Keywords:
stem cell;
kidney injury;
foscarnet;
acute kidney;
hematopoietic stem
Journal Title: Transplant Infectious Disease
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transplant Infectious Disease
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!